137 related articles for article (PubMed ID: 28238095)
21. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
Kikuchi J; Koyama D; Wada T; Izumi T; Hofgaard PO; Bogen B; Furukawa Y
J Clin Invest; 2015 Oct; 125(12):4375-90. PubMed ID: 26517694
[TBL] [Abstract][Full Text] [Related]
22. Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells.
Xu X; He Y; Miao X; Wu Y; Han J; Wang Q; Liu J; Zhong F; Ou Y; Wang Y; He S
Leuk Res; 2016 Aug; 47():54-62. PubMed ID: 27258734
[TBL] [Abstract][Full Text] [Related]
23. [Epigenetic regulation of cell adhesion-mediated drug resistance acquisition in multiple myeloma].
Furukawa Y; Kikuchi J
Rinsho Ketsueki; 2016 May; 57(5):546-55. PubMed ID: 27263778
[TBL] [Abstract][Full Text] [Related]
24. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.
Emmons MF; Gebhard AW; Nair RR; Baz R; McLaughlin ML; Cress AE; Hazlehurst LA
Mol Cancer Ther; 2011 Dec; 10(12):2257-66. PubMed ID: 21980133
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells.
Nakagawa Y; Nakayama H; Nagata M; Yoshida R; Kawahara K; Hirosue A; Tanaka T; Yuno A; Matsuoka Y; Kojima T; Yoshitake Y; Hiraki A; Shinohara M
Int J Oncol; 2014 Apr; 44(4):1376-84. PubMed ID: 24452447
[TBL] [Abstract][Full Text] [Related]
26. Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.
Shen Y; Sun Y; Zhang L; Liu H
Tumour Biol; 2017 Jun; 39(6):1010428317703941. PubMed ID: 28653881
[TBL] [Abstract][Full Text] [Related]
27. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
Damiano JS; Cress AE; Hazlehurst LA; Shtil AA; Dalton WS
Blood; 1999 Mar; 93(5):1658-67. PubMed ID: 10029595
[TBL] [Abstract][Full Text] [Related]
28. Expression of small glutamine-rich TPR-containing protein A (SGTA) in Non-Hodgkin's Lymphomas promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR).
Wang Y; Huang Y; Xu X; Tang J; Huang X; Zhu J; Liu J; Miao X; Wu Y; Yang F; Ji L; He S
Leuk Res; 2014 Aug; 38(8):955-63. PubMed ID: 24974147
[TBL] [Abstract][Full Text] [Related]
29. RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.
Tsubaki M; Takeda T; Yoshizumi M; Ueda E; Itoh T; Imano M; Satou T; Nishida S
Tumour Biol; 2016 Jul; 37(7):9099-110. PubMed ID: 26762414
[TBL] [Abstract][Full Text] [Related]
30. Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.
Xie X; Tang SC; Cai Y; Pi W; Deng L; Wu G; Chavanieu A; Teng Y
Oncotarget; 2016 Sep; 7(36):58111-58120. PubMed ID: 27517156
[TBL] [Abstract][Full Text] [Related]
31. The role of Capon in multiple myeloma.
Shen Y; Liu H; Gu S; Wei Z; Liu H
Tumour Biol; 2017 Jul; 39(7):1010428317713674. PubMed ID: 28671047
[TBL] [Abstract][Full Text] [Related]
32. ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphomas.
Zhu X; Miao X; Wu Y; Li C; Guo Y; Liu Y; Chen Y; Lu X; Wang Y; He S
Exp Cell Res; 2015 Jul; 335(2):216-23. PubMed ID: 26024773
[TBL] [Abstract][Full Text] [Related]
33. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
Bjorklund CC; Baladandayuthapani V; Lin HY; Jones RJ; Kuiatse I; Wang H; Yang J; Shah JJ; Thomas SK; Wang M; Weber DM; Orlowski RZ
Leukemia; 2014 Feb; 28(2):373-83. PubMed ID: 23760401
[TBL] [Abstract][Full Text] [Related]
34. DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas.
Ouyang Y; Zhong F; Wang Q; Ding L; Zhang P; Chen L; Wang Y; Cheng C
Leuk Res; 2016 Nov; 50():104-111. PubMed ID: 27701018
[TBL] [Abstract][Full Text] [Related]
35. miR-182 contributes to cell adhesion-mediated drug resistance in multiple myeloma via targeting PDCD4.
Wu Y; Zhu X; Shen R; Huang J; Xu X; He S
Pathol Res Pract; 2019 Nov; 215(11):152603. PubMed ID: 31540771
[TBL] [Abstract][Full Text] [Related]
36. IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells.
Münzberg C; Höhn K; Krndija D; Maaß U; Bartsch DK; Slater EP; Oswald F; Walther P; Seufferlein T; von Wichert G
J Cell Mol Med; 2015 May; 19(5):948-59. PubMed ID: 25754106
[TBL] [Abstract][Full Text] [Related]
37. ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells.
Lewis-Saravalli S; Campbell S; Claing A
Cell Signal; 2013 Sep; 25(9):1813-9. PubMed ID: 23707487
[TBL] [Abstract][Full Text] [Related]
38. Cell adhesion downregulates the expression of Homer1b/c and contributes to drug resistance in multiple myeloma cells.
Tang J; Zhou H; Wang C; Fei X; Zhu L; Huang Y; He Y; Liu J; Miao X; Wu Y; Wang Y
Oncol Rep; 2016 Mar; 35(3):1875-83. PubMed ID: 26718835
[TBL] [Abstract][Full Text] [Related]
39. Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.
Hu Q; Wang M; Wang J; Tao Y; Niu T
Oncol Res; 2024; 32(4):753-768. PubMed ID: 38560563
[TBL] [Abstract][Full Text] [Related]
40. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
Li X; Yang Y; Yi X
Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
